These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18473793)
41. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. Dong J; Cheng XD; Zhang WD; Qin JJ J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703 [TBL] [Abstract][Full Text] [Related]
42. Validating Signal Transducer and Activator of Transcription (STAT) Protein-Inhibitor Interactions Using Biochemical and Cellular Thermal Shift Assays. Attarha S; Reithmeier A; Busker S; Desroses M; Page BDG ACS Chem Biol; 2020 Jul; 15(7):1842-1851. PubMed ID: 32412740 [TBL] [Abstract][Full Text] [Related]
44. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Fletcher S; Drewry JA; Shahani VM; Page BD; Gunning PT Biochem Cell Biol; 2009 Dec; 87(6):825-33. PubMed ID: 19935868 [TBL] [Abstract][Full Text] [Related]
45. Progress towards the development of SH2 domain inhibitors. Kraskouskaya D; Duodu E; Arpin CC; Gunning PT Chem Soc Rev; 2013 Apr; 42(8):3337-70. PubMed ID: 23396540 [TBL] [Abstract][Full Text] [Related]
46. Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. Sgrignani J; Garofalo M; Matkovic M; Merulla J; Catapano CV; Cavalli A Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29843450 [TBL] [Abstract][Full Text] [Related]
47. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein. Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516 [TBL] [Abstract][Full Text] [Related]
48. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784 [TBL] [Abstract][Full Text] [Related]
49. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Beebe JD; Liu JY; Zhang JT Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035 [TBL] [Abstract][Full Text] [Related]
51. STAT3: A Potential Drug Target for Tumor and Inflammation. Hu YS; Han X; Liu XH Curr Top Med Chem; 2019; 19(15):1305-1317. PubMed ID: 31218960 [TBL] [Abstract][Full Text] [Related]
52. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Kim D; Lee IH; Kim S; Choi M; Kim H; Ahn S; Saw PE; Jeon H; Lee Y; Jon S Cancer Res; 2014 Apr; 74(8):2144-51. PubMed ID: 24576829 [TBL] [Abstract][Full Text] [Related]
53. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246 [TBL] [Abstract][Full Text] [Related]
54. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. Timofeeva OA; Gaponenko V; Lockett SJ; Tarasov SG; Jiang S; Michejda CJ; Perantoni AO; Tarasova NI ACS Chem Biol; 2007 Dec; 2(12):799-809. PubMed ID: 18154267 [TBL] [Abstract][Full Text] [Related]
55. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795 [TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bhasin D; Cisek K; Pandharkar T; Regan N; Li C; Pandit B; Lin J; Li PK Bioorg Med Chem Lett; 2008 Jan; 18(1):391-5. PubMed ID: 18006313 [TBL] [Abstract][Full Text] [Related]
57. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982 [TBL] [Abstract][Full Text] [Related]
58. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327 [TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. Gomez C; Bai L; Zhang J; Nikolovska-Coleska Z; Chen J; Yi H; Wang S Bioorg Med Chem Lett; 2009 Mar; 19(6):1733-6. PubMed ID: 19243938 [TBL] [Abstract][Full Text] [Related]
60. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Johnson FM; Saigal B; Tran H; Donato NJ Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]